

Adaptimmune Therapeutics PLC  
Form 6-K  
May 21, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**Form 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of May, 2015

Commission File Number: 001-37368

---

**ADAPT IMMUNE THERAPEUTICS PLC**

(Translation of registrant's name into English)

---

**91 Park Drive, Milton Park**  
**Abingdon, Oxfordshire OX14 4RY**  
**United Kingdom**

Edgar Filing: Adaptimmune Therapeutics PLC - Form 6-K

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  No

---

**Other Events**

On May 20, 2015, Adaptimmune Therapeutics plc (the Company ) issued a press release announcing that it has augmented its senior management team with the additions of Lini Pandite, M.D. as Senior Vice President, Clinical Development, and Anne-Marie (Annie) Martin, Ph.D. as Vice President, Head of Biomarker Research and Development. The press release is attached as Exhibit 99.1 and is incorporated by reference herein.

On May 21, 2015, the Company issued a press release announcing that it will present data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting. The press release is attached as Exhibit 99.2 and is incorporated by reference herein.

**Exhibits**

99.1 Press release dated May 20, 2015

99.2 Press release dated May 21, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Adaptimmune Therapeutics plc**

|        |                     |
|--------|---------------------|
| By:    | /s/ Margaret Henry  |
| Name:  | Margaret Henry      |
| Title: | Corporate Secretary |

Date: May 21, 2015